1Ozturk S, Sumnu A, Seyahi N, ve ark. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int Urol Nephrol 2014;46:2347-55.
2Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
3Hommos MS, De Vriese AS, Alexander MP, ve ark. The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis. A Clinicopathologic Study Mayo Clin Proc 2017; 92:1772-81.
4Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44:815-25.
5Crew RJ, Appel GB. Focal segmental glomerulosclerosis. In Greenberg A, ed. The NKF Primer on Kidney Disease, 4th ed. Philadelphia, Elsevier 2005; 178-82.
6Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15:2169-77.
7Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and treatment of focal segmental glomerulosclerosis. Neth J Med 2008;66:3-12.
8Deegens JK, Dijkman HB, Borm GF, ve ark. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008;74:1568-76.
9Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 1995;25:534-42.
10Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32:72-9.
11Pokhariyal S, Gulati S, Prasad N, ve ark. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003;16:691-6.
12Crook ED, Habeeb D, Gowdy O, Nimmagadda S, Salem M. Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population. Am J Med Sci 2005;330:19-24.
13Thomas DB, Franceschini N, Hogan SL, ve ark. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69:920-6.
14Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J 2014;7:531-7.
15Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.
16Praga M, Hernández E, Morales E, ve ark. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-8.
17Praga M, Borstein B, Andres A, ve ark. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991;17:330-8.
18Praga M, Morales E, Herrero JC, ve ark. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33:52-8.
19Schonholzer KW, Waldron M, Magi AB. Intraglomerular foam cells and human focal glomerulosclerosis. Nephron 1992;62:130-6.
20D’Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:117-34.
21Kwon YH, Han SH, Kie JH, ve ark. Clinical features and outcomes of focal segmental glomerulosclerosis pathologic variants in Korean adult patients. BMC Nephrol 2014;15:52.
22Bradeb GL, Mulhern JG, O’Shea MH, ve ark. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35:878-83.
23Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44:815-25.
24Chou YH, Lien YC, Hu FC, ve ark. Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 2012;7:1401-8.
25De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018;29:759-74.
26Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol 2001;56:89-95.
27Korbet SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:219-28.
28D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43:368-82.
29Fuiano G, Comi N, Magri P. Serial morphometric analysis of sclerotic lesions in primary “focal” segmental glomerulosclerosis. J Am Soc Nephrol 1996;7:49-55.
30Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993;22:874-83.
31Wehrmann M, Bohle A, Held H, ve ark. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33:115-2.